Recruitment

Recruitment Status
Completed
Estimated Enrollment
184

Summary

Conditions
  • Acute Myeloid Leukemia
  • Acute Leukemia
  • Aplastic Anemia
  • Chronic Myelogenous Leukemia
  • Hodgkin's Disease
  • Lymphocytic Leukemia
  • Malignant Lymphoma
  • Multiple Myeloma
  • Myelofibrosis
  • Myeloproliferative Disorder
  • Polycythemia Vera
Type
Interventional
Phase
Not Applicable
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 10 years and 65 years
Gender
Both males and females

Description

Treatment-related mortality and recurrence of disease account for the majority of treatment failures in allogeneic transplantation for advanced hematologic malignancies. The most commonly utilized conditioning regimens consist of cyclophosphamide and total-body irradiation or busulfan and cyclophosp...

Treatment-related mortality and recurrence of disease account for the majority of treatment failures in allogeneic transplantation for advanced hematologic malignancies. The most commonly utilized conditioning regimens consist of cyclophosphamide and total-body irradiation or busulfan and cyclophosphamide. Other agents such as etoposide or thiotepa are sometimes added to maximize the antileukemic effect. New conditioning regimens are however still needed to maximize efficacy and limit treatment-related deaths. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Recent data have suggested that fludarabine may be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity previously observed with cyclophosphamide/ busulfan regimens.

Tracking Information

NCT #
NCT01499147
Collaborators
Not Provided
Investigators
Principal Investigator: Damiano Rondelli, MD University of Illinois at Chicago